Skip to content Skip to footer
Subscribe Now

NEWS

Amgen
Amgen Reports the EC Approval of Imdylltra to Treat ES-SCLC
Shots: The EC has approved Imdylltra (tarlatamab) as a monotx. to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after 1L treatment with Pt-based CT Approval was based on the P-III (DeLLphi-304) trial assessing Imdelltra vs SoC CT (topotecan globally excl. Japan; lurbinectedin in the…
2 days ago
Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business for ~$2.65B
Shots: Servier has entered into an agreement with Edgewise Therapeutics to acquire its muscular dystrophy business, supporting Servier’s strategic ambition in rare neurology As per the deal, Servier will acquire the muscular dystrophy business for ~$2.65B, incl. $1.55B upfront and ~$1.1B in regulatory & commercial milestone payments; closing is expected in Q3’26 The acquisition adds Edgewise’s…
2 days ago
Haisco Enters ~$3.05B License and Research Collaboration with Lilly to Develop Novel Medicines Across Multiple Therapeutic Areas
Shots: Haisco Pharmaceutical has entered into a licensing & research collaboration with Eli Lilly to develop novel medicines across multiple therapeutic areas As per the deal, Haisco will be responsible for the discovery & identification of ~5 target programs, while Lilly will lead IND-enabling studies, clinical development, & commercialization Lilly will gain exclusive global rights…
3 days ago
Agios Pharmaceuticals Licenses Cevidoplenib from Oscotec in a ~$165M Deal
Shots: Oscotec has granted Agios exclusive global rights to cevidoplenib (PO), a spleen tyrosine kinase inhibitor, across all indications, incl. immune thrombocytopenia (ITP) As per the deal, Agios will assume full development & commercialization costs, while Oscotec will receive $25M upfront, ~$140M in development & regulatory milestones across ~3 indications in the US & EU,…
3 days ago
Eli lilly
Eli Lilly Highlights P-III (LIBRETTO-432) Trial Data on Retevmo for Early-Stage RET Fusion–Positive NSCLC at ASCO 2026
Shots: Lilly's global P-III (LIBRETTO-432) trial assessed Retevmo (selpercatinib; 160mg, BID) vs PBO in 151 pts with early-stage (IB-IIIA) RET fusion-positive NSCLC following completion of definitive radiotherapy or surgery with curative intent, & other adjuvant therapy Trial met the 1EP, improving the EFS by 83% in stage II–IIIA RET-positive NSCLC (n=109), with 24mos. EFS rates of…
3 days ago
Hanmi Pharm Inks ~$1.26B Deal with Eli Lilly to Advance Sonefpeglutide
Shots: Hanmi Pharm has granted Eli Lilly exclusive global rights (excl. Korea) to develop, manufacture & commercialize sonefpeglutide, a GLP-2 analog incorporating Hanmi's long-acting platform tech, Lapscovery As per the deal, Hanmi will receive $75M upfront & up to $1.185B in clinical development, regulatory approval, and commercialization milestone payments, with royalties following product launch Hanmi…
3 days ago
Merck
Merck Secures the US FDA Breakthrough Therapy Designation for Calderasib to Treat Newly Diagnosed Metastatic KRAS G12C-Mutant NSCLC
Shots: The US FDA has granted BTD to Merck's calderasib (MK-1084) + Keytrudafor the 1L treatment of pts with advanced or metastatic NSCLC with KRAS G12C-mutation & expressing PD-L1 (TPS ≥1%) Designation was supported by P-I (KANDLELIT-001) trial data showing calderasib monotx. (n=21) achieved a 38% ORR, calderasib + Keytruda (n=69) delivered an ORR of 77%, while…
May 29, 2026
Load more